Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Jerome Fayette, Claire Cropet, Julien Gautier, Clemence Toullec, Mickael Burgy, Amandine Bruyas, Christian Sire, Aurelie Lagrange, Florian Clatot, Benoit Calderon, Marie Vinches, Mariana Iacob, Laurent Martin, Eve Marie Neidhardt Berard, Marie-Christine Kaminsky, Damien Vansteene, Sébastien Salas

J Clin Oncol 41, June 2023 (suppl; abstr 6003)